Vixarelimab

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a publicly traded biopharma focused on immune modulation for cardiovascular and autoimmune diseases with high unmet need. Founded in 2015, its key achievement is the FDA approval and commercialization of ARCALYST® (rilonacept), the first and only therapy for recurrent pericarditis, providing a foundational revenue stream. The company's strategy leverages strategic in-licensing and targeted development of biologics with strong biologic rationale, building a balanced portfolio that spans commercial and clinical-stage assets. This approach, led by a seasoned team with a proven track record in rare diseases, aims to deliver differentiated therapies rapidly.

Therapeutic Areas